Department of Pathology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, H2.130, Dallas, TX, 75390-9073, USA.
Department of Pathology, NYU Langone Medical Center, New York, NY, USA.
Acta Neuropathol Commun. 2022 Apr 19;10(1):56. doi: 10.1186/s40478-022-01362-3.
Chordoid meningioma is a morphological variant of meningioma designated as WHO grade 2. However, the recurrence rates varied widely in different case series, and to date, a unifying molecular genetic signature has not been identified. Among 1897 meningiomas resected at our institution, we identified 12 primary chordoid meningiomas from 12 patients. Histologically, all 12 cases had predominant (> 50%) chordoid morphology. Ten were otherwise grade 1, and two were also atypical. We performed DNA global methylation profile, copy number variation analysis, and targeted next-generation sequencing on 11 chordoid meningiomas, and compared to those of 51 non-chordoid, mostly high grade meningiomas. The chordoid meningiomas demonstrated a unique methylation profile in tSNE, UMAP, and hierarchical heatmap clustering analyses of the most differentially methylated CpGs. The most common copy number variation in chordoid meningioma was loss of 1p (7/11, 64%). Three chordoid meningiomas had 2p loss, which was significantly higher than the non-chordoid control cohort (27% vs 7.2%, p = 0.035). 22q loss was only seen in the two cases with additional atypical histological features. Chordoid meningiomas were enriched in mutations in chromatin remodeling genes EP400 (8/11,73%) KMT2C (4/11, 36%) and KMT2D (4/11, 36%), and showed low or absent NF2, TERT, SMO, and AKT1 mutations. Prognosis wise, only one case recurred. This case had atypical histology and high-grade molecular features including truncating NF2 mutation, 1p, 8p, 10, 14, 22q loss, and homozygous deletion of CDKN2A/B. Progression free survival of chordoid, otherwise grade 1 meningioma was comparable to non-chordoid WHO grade 1 meningioma (p = 0.75), and significantly better than chordoid WHO grade 2 meningioma (p = 0.019). Conclusion: the chordoid histology alone may not justify a universal WHO grade 2 designation. Screening for additional atypical histological or molecular genetic features is recommended.
脊索样脑膜瘤是脑膜瘤的一种形态学变异,被指定为 WHO 分级 2 级。然而,在不同的病例系列中,复发率差异很大,迄今为止,尚未确定统一的分子遗传特征。在我们机构切除的 1897 例脑膜瘤中,我们从 12 名患者中发现了 12 例原发性脊索样脑膜瘤。组织学上,所有 12 例均具有明显 (>50%)的脊索样形态。其中 10 例为 1 级,2 例为非典型。我们对 11 例脊索样脑膜瘤进行了 DNA 全甲基化谱、拷贝数变异分析和靶向下一代测序,并与 51 例非脊索样、主要为高级别脑膜瘤进行了比较。脊索样脑膜瘤在 tSNE、UMAP 和最差异甲基化 CpG 的层次聚类分析中表现出独特的甲基化谱。脊索样脑膜瘤最常见的拷贝数变异是 1p 缺失 (7/11,64%)。3 例脊索样脑膜瘤存在 2p 缺失,明显高于非脊索样对照组 (27%比 7.2%,p=0.035)。仅在 2 例具有额外非典型组织学特征的病例中观察到 22q 缺失。脊索样脑膜瘤中染色质重塑基因 EP400(8/11,73%)、KMT2C(4/11,36%)和 KMT2D(4/11,36%)的突变富集,并且显示 NF2、TERT、SMO 和 AKT1 突变低或缺失。从预后的角度来看,只有 1 例复发。该病例具有非典型组织学和高级别分子特征,包括截断 NF2 突变、1p、8p、10、14、22q 缺失以及 CDKN2A/B 纯合缺失。脊索样、其他 1 级脑膜瘤的无进展生存率与非脊索样 WHO 1 级脑膜瘤相当 (p=0.75),明显优于脊索样 WHO 2 级脑膜瘤 (p=0.019)。结论:单纯脊索样组织学可能不足以确定普遍的 WHO 2 级分类。建议筛查额外的非典型组织学或分子遗传特征。